A new report from the Personalized Medicine Coalition highlights new personalized medicines approvals by the US Food and Drug Administration.
The year brought more FDA approvals for molecularly targeted drugs and NGS tests for personalizing cancer treatment, but reimbursement remained a stress point for industry.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
The Genetic Research Privacy Protection Act would ensure that federally funded researchers can't reveal genetic data that can identify study participants.
Since the PMI will take some time and more funds to implement, experts believe legislation is needed to ensure the project has continued support.
NextGxDx estimates more than 60,000 genetic test products would come under FDA oversight, which, if accurate, industry players fear would overburden test developers.
More than a quarter of new drugs approved by the Food and Drug Administration in 2015 were personalized medicines, the Personalized Medicine Coalition says.
The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."
The tool is aimed at facilitating a simple and efficient process that payors can use to asses a CDx's value and if further technology assessments are warranted.
Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.